Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
August 5, 2021 7:30 AM EDTToday Announced Agreement with Roche to Evaluate SY-5609 in Combination with Immunotherapy in BRAF-Mutant Colorectal Cancer Patients
Additional Dose Escalation Data for SY-5609 to be Highlighted in Oral Presentation at ESMO Congress; On Track to Advance into Phase 1 Expansion in 2H 2021
On Track to Initiate SELECT-AML-1 Randomized Phase 2 Trial of Tamibarotene in AML and Dose Confirmation Study for SY-2101 in APL in 2H 2021
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals... More
